Pfizer Inc. (PFE) Return on Assets (ROA): 3.61%
Is Pfizer Inc.’s return on assets (ROA) high or low?
Pfizer Inc.'s return on assets (ROA) of 3.61% is 49% below its 5-year average of 7.08%, near the low end of its 5-year range (0.94%–15.90%).
As of Thursday, June 18, 2026. 3.60% below its 12-month average of 3.75%.
PFE Return on Assets (ROA) Chart
PFE Average Return on Assets (ROA) Chart
PFE Current vs Average Return on Assets (ROA) Chart
PFE Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
3.61%
RETURN ON ASSETS (ROA) AVG TTM
3.75%
RETURN ON ASSETS (ROA) AVG 3Y
6.08%
RETURN ON ASSETS (ROA) AVG 5Y
7.08%
RETURN ON ASSETS (ROA) AVG 10Y
7.27%
RETURN ON ASSETS (ROA) AVG 15Y
6.02%
RETURN ON ASSETS (ROA) AVG 20Y
5.57%
CURRENT VS TTM AVG
-3.60%
CURRENT VS 3Y AVG
-40.65%
CURRENT VS 5Y AVG
-49.00%
CURRENT VS 10Y AVG
-50.33%
CURRENT VS 15Y AVG
-40.05%
CURRENT VS 20Y AVG
-35.14%
PFE Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pfizer Inc. (PFE) | $147.73B | 3.61% | 3.75% | 6.08% | 7.08% |
| Intuitive Surgical, Inc. (ISRG)vs › | $142.44B | 14.81% | 13.09% | 12.00% | 11.68% |
| Abbott Laboratories (ABT)vs › | $154.08B | 5.68% | 11.99% | 10.28% | 9.45% |
| Gilead Sciences, Inc. (GILD)vs › | $155.75B | 16.38% | 7.62% | 7.90% | 6.83% |
| CVS Health Corporation (CVS)vs › | $126.52B | 1.16% | 1.25% | 1.93% | 2.38% |
| Danaher Corporation (DHR)vs › | $125.88B | 4.42% | 4.68% | 5.89% | 6.01% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $171.57B | 6.05% | 6.31% | 6.46% | 7.20% |
| Stryker Corporation (SYK)vs › | $119.03B | 7.21% | 6.88% | 7.02% | 6.41% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $116.49B | 16.38% | 6.37% | 11.74% | 14.58% |
| Bristol-Myers Squibb Company (BMY)vs › | $112.89B | 8.41% | -0.92% | 3.28% | 1.99% |
Asset Efficiency
ROA
3.6%
ROE
8.3%
Pfizer Inc. Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Pfizer Inc. Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for Pfizer Inc. (PFE)?
- The return on assets (ROA) for PFE stock is 3.61%.
- Is Pfizer Inc.'s return on assets (ROA) high or low?
- Pfizer Inc.'s return on assets (ROA) of 3.61% is 49% below its 5-year average of 7.08%, near the low end of its 5-year range (0.94%–15.90%).
- What is the TTM average return on assets (ROA) for Pfizer Inc. (PFE)?
- The TTM average return on assets (ROA) for PFE stock is 3.75%.
- What is the 3Y average return on assets (ROA) for Pfizer Inc. (PFE)?
- The 3Y average return on assets (ROA) for PFE stock is 6.08%.
- What is the 5Y average return on assets (ROA) for Pfizer Inc. (PFE)?
- The 5Y average return on assets (ROA) for PFE stock is 7.08%.
- What is the 10Y average return on assets (ROA) for Pfizer Inc. (PFE)?
- The 10Y average return on assets (ROA) for PFE stock is 7.27%.
- What is the 15Y average return on assets (ROA) for Pfizer Inc. (PFE)?
- The 15Y average return on assets (ROA) for PFE stock is 6.02%.
- What is the 20Y average return on assets (ROA) for Pfizer Inc. (PFE)?
- The 20Y average return on assets (ROA) for PFE stock is 5.57%.
Pfizer Inc. Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 3.73% |
| 2024-12-31 | 3.76% |
| 2023-12-31 | 0.94% |
| 2022-12-31 | 15.90% |
| 2021-12-31 | 12.20% |
| 2020-12-31 | 5.94% |
| 2019-12-31 | 9.72% |
| 2018-12-31 | 7.00% |
| 2017-12-31 | 12.40% |
| 2016-12-31 | 4.20% |
| 2015-12-31 | 4.16% |
| 2014-12-31 | 5.36% |
| 2013-12-31 | 6.77% |
| 2012-12-31 | 5.27% |
| 2011-12-31 | 4.63% |
| 2010-12-31 | 4.24% |
| 2009-12-31 | 4.05% |
| 2008-12-31 | 7.22% |
| 2007-12-31 | 7.12% |
| 2006-12-31 | 9.60% |
| 2005-12-31 | 6.47% |
| 2004-12-31 | 9.16% |
| 2003-12-31 | 3.35% |
| 2002-12-31 | 19.69% |
| 2001-12-31 | 19.89% |
| 2000-12-31 | 11.12% |
| 1999-12-31 | 15.45% |
| 1998-12-31 | 18.31% |
| 1997-12-31 | 14.43% |
| 1996-12-31 | 13.15% |
Related Metrics
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla